Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01202279
Other study ID # 2009-MUCD-001
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 2009
Est. completion date July 2010

Study information

Verified date December 2020
Source Reckitt Benckiser LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo


Recruitment information / eligibility

Status Completed
Enrollment 1179
Est. completion date July 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - patients aged 18 to 75 yrs of age presenting at a clinical site with symptoms diagnostic for an acute upper respiratory tract infection within the last 5 days Exclusion Criteria: - patients who had chronic, recurring respiratory signs and symptoms due to conditions such as chronic allergic rhinitis, chronic sinusitis or chronic bronchitis which in the investigator's opinion, confounded interpretation of symptom ratings for the acute upper respiratory infection. Also excluded were patients with a fever greater than 101 degrees F.

Study Design


Related Conditions & MeSH terms

  • Acute Upper Respiratory Track Infection
  • Infection

Intervention

Drug:
Guaifenesin
1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
Device:
Placebo
Placebo bid for 7 days

Locations

Country Name City State
United States Integrated Medical Research, PC Ashland Oregon
United States Immedicenter Bloomfield New Jersey
United States TriCities Medical Research Bristol Tennessee
United States Med Center Carmichael California
United States Parsons Avenue Medical Clinic Columbus Ohio
United States Legacy Clinical Research, LLC, 1204 W. Willow Road, Suite B Enid Oklahoma
United States Sterling Research Group, Ltd., 650 Sprucewood Lane Erlanger Kentucky
United States Research Center of Fresno, 3636 N. First Street, Suite 141 Fresno California
United States Harleysville Medical Associates, 176 Main Street Harleysville Pennsylvania
United States Peters Medical Research High Point North Carolina
United States Kastelic MD & Associates, 322 Warren Street, Suite 300 Johnstown Pennsylvania
United States Clinical Research Advantage, Inc. Mesa Arizona
United States Koch Family Medicine, 81A E. Queenwood Road Morton Illinois
United States Palmetto Medical Research, 180 Wingo Way, Suite 203 Mount Pleasant South Carolina
United States Coastal Connecticut Research, LLC, 342 Montauk Avenue New London Connecticut
United States Glasgow Family Practice Newark Delaware
United States Durham Physicians, P.C. Penndel Pennsylvania
United States Village Health Partners Plano Texas
United States Clinical Associates Research, 750 Main Street, Suite 310 Reisterstown Maryland
United States (Piedmont Medical Research Assoc., Inc. d/b/a), Crescent Medical Research Salisbury North Carolina
United States Coastal Medical Research Group, Inc., 47 Santa Rosa Street San Luis Obispo California
United States Park Place Family Practice & Internal Medicine Taylor Michigan
United States Independence Family Medicine, 813 Independence Blvd., Suite A Virginia Beach Virginia
United States Amherst Family Practice, 1867 Amherst Street Winchester Virginia

Sponsors (1)

Lead Sponsor Collaborator
Reckitt Benckiser Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antibiotic Sparing Number of patients who received an antibiotic Day 7
Primary Change From Baseline in Total Symptom Score of the Wisconsin Upper Respiratory Symptom Survey - 21 (WURSS-21). WURSS-21 is made up of 21 questions with a scoring from 0 = no symptom to 7 = severe symptom. With a minimum score of 0 to a maximum score of 147. Baseline and 7 Days